11.07.25 -- STREAM Edition: Innovating Next-Generation ADC Constructs

NewYorkBIO's Jennifer Hawks Bland discusses growing interest in bringing biomanufacturing back to New York state, noting that NewYorkBIO works with Empire State Development to attract these facilities, offering connections and support to integrate new companies into the local ecosystem. 

In this roundtable discussion, a trio of distinguished experts in AAV purification and process development share their expertise and best practices in tackling and solving downstream challenges.

Thomas Levenson, MIT professor and author, acknowledges the microbiome as a potential new frontier for germ theory, acknowledging its immense complexity since traditional germ theory focuses on individual microbes with clear cause-and-effect relationships, while the microbiome is an intricate ecosystem within our bodies.

If you are in the process of developing a complex or sensitive injectable drug, learn about containment solutions to mitigate your risks and help you get your drug to the patient faster.

Explore the application of a platform in creating CHO cell lines for manufacturing multi-chain biologics, emphasizing the uniformity of the pools generated by this platform in terms of titer and the rapid selection of these pools.

In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists share their thoughts on what constitutes a next-generation ADC and discuss innovations in the space, particularly in linkers, payloads, and consistent molecular homogeneity with respect to drug-antibody ratio (DAR).

Unlock next-generation nanoparticle and LNP manufacturing. Achieve high throughput, minimal waste, and superior quality with a compact, automated, and contamination-controlled system.